Diagnosing GIST: Key Challenges and Treatment Insights
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions.
Related Articles
First neighbourhood health services to be rolled out from September | Nursing Times
The first of the new neighbourhood health services will be rolled out across 42 sites in England from September, the government has announced.
‘Moving the needle doesn’t require a full-scale nursing revolution’ | Nursing Times
Amantle Gabolekwe from Botswana argues that today’s student nurses are future leaders and can make positive changes now, one step at a time.
Therapies Which Received FDA Approval in July: What You Should Know
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology indications and cancer types.
Therapies Which Received FDA Approval in July: What You Should Know
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology indications and cancer types.
Layers of Pain: Decoding the Multifaceted Toxicity of Breast Cancer
Breast cancer care differs around the world, revealing urgent unmet needs in Nepal, where access, support, and treatment remain out of reach for many.
Oncology Pharmacy Virtual Office Hours Highlight Emerging Strategies for Implementing Bispecific Antibodies
This spring, ACCC hosted 2 virtual office hours sessions featuring oncology pharmacists with expertise in using bispecific antibodies. Participants shared practical insights, challenges, and strategies…
Advocating for AYAs With Osteosarcoma
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, Osteosarcoma, a rare type of bone cancer that primarily affects adolescents and…
Celebrating Survival After Transplant: Appreciating My Donor
I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life she helped me…
Understanding Therapeutic Options for ER+/HER2- Metastatic Breast Cancer
Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, HER2-negative stage 4 breast cancer.
FDA Approves Stoboclo and Osenvelt as Biosimilars Across Some Cancers
Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.